Furthermore, inotuzumab ozogamicin, an anti-CD22 antibody-drug conjugate, has been approved in the EU and US for the treatment of relapsed or refractory (R/R) B cell precursor acute lymphoblastic leukemia (BCP-ALL), providing another treatment option for these patients [3]. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.